Metastatic Sarcoma Clinical Trial
Official title:
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. PM01183 is a new drug that is believed to bind DNA cause double strands of DNA to break. This drug has been studied in previous research studies, and these suggest that it may slow or stop the growth of cancers. The FDA (the U.S. Food and Drug Administration) has not approved PM01183 as a treatment for any disease. In this research study, the investigators are trying to assess the effects, good or bad, that PM01183, administered either alone or in combination with gemcitabine or doxorubicin has on metastatic or unresectable sarcoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01106872 -
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
|
Phase 1 | |
Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 | |
Completed |
NCT01112384 -
A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas
|
Phase 2 | |
Completed |
NCT03357315 -
Mix Vaccine for Metastatic Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05448820 -
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04595747 -
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Not yet recruiting |
NCT06298916 -
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04693377 -
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
|
N/A | |
Recruiting |
NCT03168061 -
Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05835154 -
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
|
N/A | |
Not yet recruiting |
NCT04199026 -
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
|
Early Phase 1 | |
Not yet recruiting |
NCT06235125 -
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
|
Phase 1 | |
Recruiting |
NCT04771520 -
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
Completed |
NCT03823144 -
Intravital Microscopy in Human Solid Tumors
|
N/A | |
Recruiting |
NCT04430725 -
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
|
||
Completed |
NCT02192346 -
α-TEA in Advanced Cancer
|
Phase 1 | |
Terminated |
NCT02609984 -
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
|
Phase 2 |